Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

NCT03204396 on ClinicalTrials.gov · last registry update 2022-09-13

An unusually large phase 2: 256 participants, more than double the 110 typical for the stage. The sponsor logged completion for 30 July 2022. Primary outcome, as filed: Point prevalence abstinence rate at week 12. dulaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: University Hospital, Basel, Switzerland
Sponsor type: Other
Enrollment: 256
Started: 2017-06-26
Primary completion: 2022-07-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Point prevalence abstinence rate at week 12

Conditions studied

Glucagon-like Peptide-1 · Smoking Cessation · Weight Change, Body · Craving

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.